Hero_PHD_03_03_09XProteomics.ppt  --- Hero's preliminary report

CopyXofXPlasmaXforXProteomicsXtoXRBMX010809.desc -- transmission email

CopyXofXPlasmaXforXProteomicsXtoXRBMX010809.xls 
     --- mapping sample id to subject timepoint

proteomics-key.txt -- extract of above
   Split into symptomatic / asymptomatic
   grouped by subject, but no particular order of time points
, separated entries -- sample from subject 5

Flu005,5 hours (Day 0),DU08-04S20832
Flu005,Baseline (Day -1),DU08-04S25037
Flu005,Pre-Challenge(Day 0),DU08-04S23540
Flu005,12 hours (Day 0),DU08-04S25553
Flu005,21.5 hours (Day 1),DU08-04S21285
Flu005,84 hours (Day 3),DU08-04S23259
Flu005,60 hours (Day 2),DU08-04S21468

proteomics-key-tab.txt -- easier to read, harder to parse
	
DU08-04XFluXproteomicXresultsX021709.xls -- the proteomics data
DU08-04XFluXproteomicXresultsX021709.csv  -- in csv format

Row 1 starting in 3rd columm -- column header -- protein name
Row 2  ""                       units
Row 3  ""   Least Detectable Dose
Row 4  ""   RBM Low Plasma Range
Row 5  ""   RBM High Plasma Range
Row 6 on Sample id followed by (starting in column 3) the measurments.
(141 samples)

Meta data removed from the .csv file
RBM Order # 105222 
Customer: National Center for Genome Resources
Group Designation: Flu Challenge
Customer Study # DU08-04
Investigator: Stephen Kingsmore
Received Date: 04 February 2009; Date Testing Completed: 16 February 2009
Type of samples 141 Human EDTA Plasma

The least detectable dose (LDD) was determined as the mean + 3 standard
deviations of 20 blank readings. Results below the LDD will be more variable
than results above the LDD

<LOW> values reflect samples not measurable on the standard curve.